Skip to main content

Idarubicin

  • Chapter
  • 928 Accesses

Abstract

1. Stop injection/infusion immediately

2. Get extravasation kit

3. Put on (sterile) gloves

4. Replace infusion lead or syringe with 5 ml disposable syringe and aspirate slowly as much as possible of the extravasated drug; Cave! do not exert pressure on extravasation area

This is a preview of subscription content, log in via an institution.

Buying options

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   159.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Original articles

  1. Lu K, Savaraj N, Kavanagh J, et al: Clinical pharmacology of 4-demethoxydaunorubicin (DMDR). Cancer Chemother Pharmacol 17: 143–148, 1986.

    Article  PubMed  CAS  Google Scholar 

  2. Bertelli G, Gozza A, Forno GB, et al: Topical dimethylsulfoxide for the prevention of soft tissue injury after extravasation of vesicant cytotoxic drugs: a prospective clinical study. J Clin Oncol 13: 2851–2855, 1995.

    PubMed  CAS  Google Scholar 

  3. Bertelli G, Dini D, Forno G, et al: Dimethylsulphoxide and cooling after extravasation of antitumour agents. Lancet 341: 1098–1099, 1993.

    Article  PubMed  CAS  Google Scholar 

  4. Langer SW, Sehested M, Jensen PB: Treatment of anthracycline extravasation with dexrazoxane. Clin Cancer Res 6: 3680–3686, 2000.

    PubMed  CAS  Google Scholar 

Secondary literature

  1. Bertelli G: Prevention and management of extravasation of cytotoxic drugs. Drug Safety 12: 245–255, 1995.

    Article  PubMed  CAS  Google Scholar 

  2. Krämer I, Stützle M: Zytostatika-Paravasation – Wie ist vorzugehen? Krankenhauspharmazie 23: 261–268, 2002.

    Google Scholar 

  3. Schneider G: Paravasate von Zytostatika. Diagnostik und Therapie. Aina S. Schneider Verlag, 6th edition: 1–17, 1999.

    Google Scholar 

  4. Stanley A: Managing complications of chemotherapy administration. In: Allwood M, Stanley A, Wright P (eds) The Cytotoxics Handbook. Radcliffe Medical Press, 4th edition: 119–193, 2002.

    Google Scholar 

  5. Mullin S, Beckwith MC, Tyler LS: Prevention and management of antineoplastic extravasation injury. Hosp Pharm 35: 57–76, 2000.

    Google Scholar 

  6. Gain M, Melzer S, Meyer-Jürshof A, et al: Idarubicin: Behandlung von Paravasaten In: Gain M, et al (eds) ADKA-Zytostatika–Handbuch, Pharmazeutisch-wissenschaftliche Monographien. Verlag Heiner Biller, vol 7, 34–35, 2003.

    Google Scholar 

  7. Kraft A, Weinig S, Edinger M, et al: Anthrazyklin-Extravasate. Der Onkologe 6: 674–686, 2000.

    Article  Google Scholar 

  8. Jordan K, Grothe W, Schmoll HJ: Paravasation von Zytostatika: Prävention und Therapie. Dtsch Med Wochenschr 130: 33–37, 2005.

    Article  PubMed  CAS  Google Scholar 

  9. Ener RA, Meglathery SB, Styler M: Extravasation of systemic hemato-oncological therapies. Ann Oncol 15: 858–862, 2004.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

Copyright information

© 2010 Springer-Verlag/Wien

About this chapter

Cite this chapter

Mader, I., Fürst-Weger, P., Mader, R., Nogler-Semenitz, E., Wassertheurer, S. (2010). Idarubicin. In: Extravasation of Cytotoxic Agents. Springer, Vienna. https://doi.org/10.1007/978-3-211-88893-3_39

Download citation

  • DOI: https://doi.org/10.1007/978-3-211-88893-3_39

  • Publisher Name: Springer, Vienna

  • Print ISBN: 978-3-211-88889-6

  • Online ISBN: 978-3-211-88893-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics